H.KriebardisA
[DOI] [PubMed] [Google Scholar] 44.Cifarelli V., Beeman S.C., Smith G.I., Yoshino J., Morozov D., Beals J.W., Kayser B.D., Watrous J.D., Jain M., Patterson B.W., et al
Krawczyk, M
Participants received weekly doses of one of the following: CagriSema 2.4/2.4 milligrams (mg), meaning 2.4 mg of cagrilintide and 2.4 mg of semaglutide CagriSema 1 / 1 mg, or 1 mg of cagrilintide and 1 mg of semaglutide 2.4 mg of semaglutide 1 mg of semaglutide 2.4 mg of cagrilintide a placebo
Conclusion Retatrutide and CagriSema represent the next generation of obesity pharmacotherapy
There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States